Hsp90 inhibition sensitizes DLBCL cells to cisplatin.

Saved in:
Bibliographic Details
Title: Hsp90 inhibition sensitizes DLBCL cells to cisplatin.
Authors: Schmidt L; Department of Hematology, Aalborg University Hospital, Søndre Skovvej 15, 9000, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Issa II; Department of Hematology, Aalborg University Hospital, Søndre Skovvej 15, 9000, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Haraldsdóttir H; Department of Hematology, Aalborg University Hospital, Søndre Skovvej 15, 9000, Aalborg, Denmark., Hald JL; Department of Hematology, Aalborg University Hospital, Søndre Skovvej 15, 9000, Aalborg, Denmark., Schmitz A; Department of Hematology, Aalborg University Hospital, Søndre Skovvej 15, 9000, Aalborg, Denmark., Due H; Department of Hematology, Aalborg University Hospital, Søndre Skovvej 15, 9000, Aalborg, Denmark., Dybkær K; Department of Hematology, Aalborg University Hospital, Søndre Skovvej 15, 9000, Aalborg, Denmark. k.dybkaer@rn.dk.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. k.dybkaer@rn.dk.; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. k.dybkaer@rn.dk.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Apr; Vol. 89 (4), pp. 431-440. Date of Electronic Publication: 2022 Feb 21.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1432-0843
DOI:10.1007/s00280-022-04407-5